As of May 27
| +0.28 / +1.68%|
The 5 analysts offering 12-month price forecasts for Theravance Inc have a median target of 15.00, with a high estimate of 18.00 and a low estimate of 7.00. The median estimate represents a -11.24% decrease from the last price of 16.90.
The current consensus among 6 polled investment analysts is to Hold stock in Theravance Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.